Number of Layoffs Undisclosed As Sequenom Consolidates Lab Facilities

SAN DIEGO, May 27, 2015 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that its wholly owned subsidiary, Sequenom Laboratories, will move its laboratory operations in Grand Rapids, Michigan to its facility in Raleigh Durham, North Carolina.  Sequenom Laboratories' cystic fibrosis carrier screen test will now be performed at the North Carolina laboratory location. 

"The expansion of our North Carolina laboratory operations to include our HerediT^® CF carrier screen test will enable us to continue to provide high quality and meaningful test offerings to physicians and their patients while continuing to build value for our shareholders," said William Welch, President and Chief Executive Officer of Sequenom.

Sequenom Laboratories will discontinue its SensiGene^® Fetal RHD Genotyping test as part of the laboratory consolidation.  Test volumes and revenues from the SensiGene Fetal RHD test historically have not been material to the company's financial results.  Sequenom Laboratories will reintroduce this test should medical committees issue guidelines that support broader use and reimbursement of RHD genotyping.  Sequenom will provide transition services and outplacement assistance to affected employees.

About Sequenom 

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information.  To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care.  Branded under the names HerediT^®, HerediT^® UNIVERSAL, MaterniT21^® PLUS, NextView, SensiGene^® and VisibiliT, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.  Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies.  Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM^®, HerediT^®, HerediT^® UNIVERSAL, MaterniT21^® PLUS, NextView, SensiGene^®, VisibiliT and Sequenom Laboratories, are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.

Forward-Looking

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of innovative products and services and the ability to expand the North Carolina laboratory location.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made.  The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sequenom-laboratories-to-consolidate-michigan-and-north-carolina-facilities-300089580.html

SOURCE Sequenom, Inc.